Evaxion Operating Margin from 2010 to 2026
| EVAX Stock | USD 3.31 0.09 2.65% |
Check Evaxion Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Evaxion Biotech's main balance sheet or income statement drivers, such as Interest Income of 277.5 K, Depreciation And Amortization of 376.7 K or Interest Expense of 1 M, as well as many indicators such as Price To Sales Ratio of 1.48, Dividend Yield of 0.0 or Days Sales Outstanding of 162. Evaxion financial statements analysis is a perfect complement when working with Evaxion Biotech Valuation or Volatility modules.
Evaxion | Operating Margin | Build AI portfolio with Evaxion Stock |
The evolution of Operating Margin for Evaxion Biotech AS provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Evaxion Biotech compares to historical norms and industry peers.
Latest Evaxion Biotech's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Evaxion Biotech AS over the last few years. It is Evaxion Biotech's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Evaxion Biotech's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.40 % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Evaxion Operating Margin Regression Statistics
| Arithmetic Mean | (251.15) | |
| Coefficient Of Variation | (46.92) | |
| Mean Deviation | 87.17 | |
| Median | (304.07) | |
| Standard Deviation | 117.84 | |
| Sample Variance | 13,887 | |
| Range | 300 | |
| R-Value | 0.66 | |
| Mean Square Error | 8,332 | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 15.44 | |
| Total Sum of Squares | 222,195 |
Evaxion Operating Margin History
About Evaxion Biotech Financial Statements
Evaxion Biotech investors use historical fundamental indicators, such as Evaxion Biotech's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Evaxion Biotech. Please read more on our technical analysis and fundamental analysis pages.
Evaxion Biotech AS, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company was incorporated in 2008 and is headquartered in Hrsholm, Denmark. Evaxion Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.